A large language model (LLM)-based multi-agent framework for risk stratification and treatment recommendations in localized prostate cancer (locPCa).

U Umair Ayub (1Mayo Clinic, Division of Hematology/Oncology, Department of Internal Medicine, Phoenix, United States) S Syed Arsalan Ahmed Naqvi (Mayo Clinic, Phoenix, AZ) S Salman Ayub Jajja (NYMC-LANDMARK MEDICAL CENTER, RI, Woonsocket, Rhode Island, United States) M Muhammad Umar Afzal (Mayo Clinic Arizona, Scottsdale, AZ) J Ji-Eun Irene Yum (Mayo Clinic Alix School of Medicine, Phoenix, AZ) K Kaneez Zahra Rubab Khakwani (University of Arizona, Tucson, AZ) C Chitta Baral (Arizona State Univeristy (ASU), Tempe, AZ) S Sumanta Kumar Pal (Department of Medical Oncology City of Hope Comprehensive Cancer Center Duarte California USA) N Neeraj Agarwal (Division of Medical Oncology Department of Internal Medicine Huntsman Cancer Institute University of Utah Salt Lake City Utah USA) A Abhishek Tripathi (Department of Medical Oncology and Therapeutics Research City of Hope Comprehensive Cancer Center Duarte California USA) J Jack Andrews (Mayo Clinic Arizona, Phoenix, AZ) H Haidar Abdul-Muhsin (Mayo Clinic Arizona, Phoenix, AZ) D Daniel M. Frendl (Mayo Clinic Arizona, Phoenix, AZ) M Mark Raymond Waddle (Department of Radiation Oncology, Mayo Clinic Rochester, Rochester, MN) D Daniel S Childs (Division of Medical Oncology, Mayo Clinic Rochester, Rochester, MN) A Alan Haruo Bryce (Mayo Clinic Arizona, Phoenix, AZ) Y Yousef Zakharia (Division of Hematology and Medical Oncology, Department of Internal Medicine Mayo Clinic Phoenix Arizona USA) P Parminder Singh (Department of Medicine, Mayo Clinic Alix School of Medicine, Phoenix, AZ) I Irbaz Bin Riaz (Irbaz Bin Riaz, MD, PhD; R. Bryan Rumble, MSc; Thomas A. Hope, MD; Giuseppe Procopio, MD; and Neha Vapiwala, MD; Mayo Clinic, Phoenix, AZ; American Society of Clinical Oncology, Alexandria, VA; University of California, San Francisco, San Francisco, CA; Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy; and University of Pennsylvania Abramson Cancer Center, Philadelphia, PA)

Abstract

5108 Background: We previously proposed a hybrid framework combining LLMs and rule based algorithm (RBA) for automating risk stratification in locPCa. Herein, we aim to validate the risk stratification agent (RSA) in a prospective cohort, develop & evaluate the treatment recommendation agent (TRA) based on NCCN guidelines, and develop an interactive interface to facilitate clinicians for accurate risk stratification and treatment recommendations at the point of care. Methods: This study included pts with locPCa (2004-2024) presenting at Mayo Clinic with at least 1 positive prostate biopsy and MRI report available. For RSA prospective validation, GPT4 extracted key phenotypic variables (PSA, T stage, prostate volume, number of cores, Gleason patterns, grade group) from unstructured MRI and biopsy reports using a zeroshot prompt. An RBA then classified pts into NCCN risk groups. The agent performance was compared with the treating clinician's documentation and evaluated against gold-standard labels manually annotated by two independent clinicians. For development of TRA, two experiments were performed using GPT4 with and without retrieval-augmented generation (RAG) to generate treatment plans. Generated treatment plans were evaluated using NCCN guideline-informed treatment decision tree based algorithm (DTA). Evaluation metrics, weighted – accuracy (acc) and F1, were computed. A clinician facing interface (lisr.org/risk) was developed to provide accurate risk stratification and treatment plans. Results: A total of 858 pts were included (500 for prospective validation, 358 for treatment recommendations). Prospective validation for RSA demonstrated a higher F1 score of 0.89 compared to the treating clinician (F1: 0.58). Treatment recommendation experiments showed that GPT4 with RAG achieved higher acc (64% full – all correct treatment options and 36% partial – at least 1 correct treatment option) compared to GPT4 alone (35% and 65%, respectively). Sensitivity analysis using DTA-informed GPT4 note generation achieved 94% full acc and 6% partial acc. GPT4 alone generated hallucinated treatment options in 71% of cases, while GPT4 with RAG reduced this to 32%. Conclusions: The multi-agent framework based on LLM and RBA achieves high accuracy in risk stratification and treatment recommendation for locPCa. A multi-agent framework with an interactive interface holds high promise to enable efficient, accurate decision-making, and improve locPCa management at the point of care Performance evaluation. RSA(acc; F1) % TRA(full acc; partial acc) % Clinician RSA* GPT4 RAG+GPT4 DTA+GPT4 Overall 60; 58 89; 89 29; 71 64; 36 94; 6 V. High 94; 33 96; 96 55; 45 69; 31 93; 7 High 46; 52 92; 89 - - - Int. Unf 80; 61 91; 90 5; 95 38; 62 93; 7 Int. Fav 57; 64 84; 87 0; 100 98; 2 100; 0 Low 57; 65 87; 80 100; 0 95; 5 90; 10 V. Low 8; 13 50; 67^ - - - *Statistical significance (p<0.01) except for ^V. Low.

Article Details

Volume / Issue Vol. 43, Issue 16_suppl
Published June 01, 2025
Pages 5108-5108
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (19)

U

Umair Ayub

1Mayo Clinic, Division of Hematology/Oncology, Department of Internal Medicine, Phoenix, United States

S

Syed Arsalan Ahmed Naqvi

Mayo Clinic, Phoenix, AZ

S

Salman Ayub Jajja

NYMC-LANDMARK MEDICAL CENTER, RI, Woonsocket, Rhode Island, United States

M

Muhammad Umar Afzal

Mayo Clinic Arizona, Scottsdale, AZ

J

Ji-Eun Irene Yum

Mayo Clinic Alix School of Medicine, Phoenix, AZ

K

Kaneez Zahra Rubab Khakwani

University of Arizona, Tucson, AZ

C

Chitta Baral

Arizona State Univeristy (ASU), Tempe, AZ

S

Sumanta Kumar Pal

Department of Medical Oncology City of Hope Comprehensive Cancer Center Duarte California USA

N

Neeraj Agarwal

Division of Medical Oncology Department of Internal Medicine Huntsman Cancer Institute University of Utah Salt Lake City Utah USA

A

Abhishek Tripathi

Department of Medical Oncology and Therapeutics Research City of Hope Comprehensive Cancer Center Duarte California USA

J

Jack Andrews

Mayo Clinic Arizona, Phoenix, AZ

H

Haidar Abdul-Muhsin

Mayo Clinic Arizona, Phoenix, AZ

D

Daniel M. Frendl

Mayo Clinic Arizona, Phoenix, AZ

M

Mark Raymond Waddle

Department of Radiation Oncology, Mayo Clinic Rochester, Rochester, MN

D

Daniel S Childs

Division of Medical Oncology, Mayo Clinic Rochester, Rochester, MN

A

Alan Haruo Bryce

Mayo Clinic Arizona, Phoenix, AZ

Y

Yousef Zakharia

Division of Hematology and Medical Oncology, Department of Internal Medicine Mayo Clinic Phoenix Arizona USA

P

Parminder Singh

Department of Medicine, Mayo Clinic Alix School of Medicine, Phoenix, AZ

I

Irbaz Bin Riaz

Irbaz Bin Riaz, MD, PhD; R. Bryan Rumble, MSc; Thomas A. Hope, MD; Giuseppe Procopio, MD; and Neha Vapiwala, MD; Mayo Clinic, Phoenix, AZ; American Society of Clinical Oncology, Alexandria, VA; University of California, San Francisco, San Francisco, CA; Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy; and University of Pennsylvania Abramson Cancer Center, Philadelphia, PA